30 closest matches · ranked by relevance
Diabetes Mellitus, Type 1
Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Type 2 Diabetes · Insulin Resistance
Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min
Type I Diabetes Mellitus
Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
PCOS
Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min
Atopic Dermatitis/Eczema · Type 2 Diabetes
Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
Type 1 Diabetes
Primary: Change in GAD65 Autoantibody Titer (DK Units/mL) — 247; 234; 193; 196 DK Units/mL
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
Diabetes · Diabetes Mellitus, Type 2
Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
Diabetes, Gestational · Diabetes, Type 2
Primary: Glycemic Control — 109.5; 107.4 mg/dL
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.05; -1.36 percentage of glycosylated haemoglobin
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.28; -1.07; -1.26 percentage of glycosylated haemoglobin
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Type 2 Diabetes Mellitus
Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl
Sub-optimal Vitamin D Status · Pre-diabetes · Insulin Resistance
Primary: Change in Insulin Resistance — 37.4; 36.3 μmol/kg/min (Step 2 GIR corrected)
Type 2 Diabetes
Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL
Gestational Diabetes
Primary: Birth Weight Per Arm — 3604; 3589 g
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.59; -0.03 Percent — p=<0.001
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Diabetes · Hyperglycemia
Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Daily Insulin Dose at Week 24 — 19.0; 23.8 International Units (IU) — p=0.009